Hepar-C: A cross-sectional study investigating general population knowledge, attitudes, and behaviors regarding hepatitis C screening in the Latium Region, Italy, October 2022 to May 2023
Public Health · 2025
DOI: 10.1016/j.puhe.2025.01.009 ↗Kurz gefasst
Querschnittstudie in der Zeitschrift Public Health, 2025. Verfasst von Giulia Santolini und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Public Health and Infectious Diseases, Sapienza University of Rome, Italy. Hauptthemen laut MEDLINE: Hepatitis C, Health Knowledge, Attitudes, Practice, Mass Screening. Die Arbeit nennt 19 Literaturangaben.
Abstract (Originalsprache)
OBJECTIVES: The study aimed to gather information about the target population's knowledge, attitudes, and behaviors regarding HCV screening to develop effective communication strategies and improve service offerings. STUDY DESIGN: This was a Cross-Sectional study. METHODS: A target population random sample was submitted a phone questionnaire based on the Health Belief Model (HBF), containing 4 sections on perceived HCV susceptibility and severity, screening benefits and barriers. Each person interviewed was finally invited to adhere to the screening. Prevalence was estimated using a 95 % C.I., and association between sociodemographic characteristics, HBF attitudes, and screening adherence following the interview was assessed. RESULTS: Survey involved 641 participants. HCV susceptibility was perceived by 4.8 % (95 % CI 3.23-6.57) and HCV severity by 69.4 % (95 % CI 65.83-72.97), 95 % (95 % CI 93.3-96.6) acknowledged screening benefits and 88 % (95 % CI 85.4-90.5) perceived no barriers. Insufficient or no information about HCV or the screening was received by the 49.0 % (95 % CI 45.1-52.8) of people interviewed. Among these people, in the 2 months aftermath, 17.6 % carried out the HCV screening. Perception of screening barriers was associated with low education level (OR 1.83, P = 0.02). CONCLUSIONS: Low adherence to the HCV screening could be explained with a poor perception of HCV susceptibility and gravity by the target population particularly with socioeconomic hurdles. Forthcoming communication campaign would need to focus on those factors to improve adherence.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Public Health and Infectious Diseases, Sapienza University of Rome, Italy.
- Department of Public Health and Infectious Diseases, Sapienza University of Rome, Italy. Electronic address: andrea.bongiovanni@uniroma1.it.
- Prevention Department, Public Health Services, ASL Roma 5, Tivoli, Lazio, Italy.
- Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy.
Zitieren
APA
Santolini, G., Bongiovanni, A., Abbondanzieri, A., Ambrosone, C., Bruno, E., Schiariti, E., De Angelis, F., Flammini, A. M., Formosa, V., Mantia, F. E., Marfurt, C., & Perra, A. (2025). Hepar-C: A cross-sectional study investigating general population knowledge, attitudes, and behaviors regarding hepatitis C screening in the Latium Region, Italy, October 2022 to May 2023. Public Health. https://doi.org/10.1016/j.puhe.2025.01.009
Vancouver
Santolini G, Bongiovanni A, Abbondanzieri A, Ambrosone C, Bruno E, Schiariti E, et al. Hepar-C: A cross-sectional study investigating general population knowledge, attitudes, and behaviors regarding hepatitis C screening in the Latium Region, Italy, October 2022 to May 2023. Public Health. 2025. doi:10.1016/j.puhe.2025.01.009
BibTeX
@article{Santolini2025,
author = {Santolini, Giulia and Bongiovanni, Andrea and Abbondanzieri, Alessio and Ambrosone, Cristina and Bruno, Elena and Schiariti, Elisabetta and De Angelis, Federica and Flammini, Azzurra Maria and Formosa, Valeria and Mantia, Francesco Ettore and Marfurt, Carlo and Perra, Alberto},
title = {Hepar-C: A cross-sectional study investigating general population knowledge, attitudes, and behaviors regarding hepatitis C screening in the Latium Region, Italy, October 2022 to May 2023},
journal = {Public Health},
year = {2025},
doi = {10.1016/j.puhe.2025.01.009}
}
EUVIMED